Deborah Glasser: Nasdaq Bell Celebrating FDA Approval of Novel ITP Therapy
Deborah Glasser, Head of Specialty Care for Sanofi, shared a post on LinkedIn:
”Yesterday, I had the opportunity to ring the Nasdaq closing bell, surrounded by Sanofi colleagues and representatives from the Platelet Disorder Support Association – PDSA. I’m so grateful that PDSA joined us on this special occasion to celebrate ITP Awareness Month, and to recognize the recent FDA approval of a novel treatment. By targeting root causes through multi-immune modulation, this new medicine represents a significant step forward for patients living with immune thrombocytopenia (ITP), a complex immune dysregulation disease, which can cause symptoms that disrupt daily life.
This moment reflects the power of science, collaboration, and our shared commitment to improving patient outcomes. At Sanofi, we continue to push the boundaries of immunoscience to make a meaningful difference for individuals affected by rare conditions like ITP.”
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 17:27Masudah Paleker: Suboptimal Warfarin Control in South Africa
-
Aug 22, 2026, 17:26Maxime Dely: Sickle Cell Disease – Behind Every Exchange, There Is a Donor
-
Aug 22, 2026, 17:05Mostafa Elshazly: Managing Anticoagulant-Related Bleeding in Clinical Practice
-
Aug 22, 2026, 17:01Cesarovic Nikola: FDA Data Reanalysis Raises Questions About Moderna’s mFLUSIVA Risk-Benefit Profile
-
Aug 22, 2026, 16:38Andreas Linkermann: Decoding the Chain Reaction of Ferroptotic Cell Death
-
Aug 22, 2026, 16:33Nicolas Hulscher: FDA Data Reanalysis Raises Alarms Over Moderna’s MFLUSIVA
-
Aug 22, 2026, 16:19Moti Haim: Transforming AF Care in the Elderly
-
Aug 22, 2026, 16:12Hussam Hammoud: A Slap Is Not “Just a Slap” When the Patient Has Hemophilia
-
Aug 22, 2026, 15:53Howard Smith: Publix’s GreenWise Organic Frozen Berries Have E. coli Contamination